Nuvalent Inc   (NUVL)
Other Ticker:  
Price: $87.2600 $4.03 4.842%
Day's High: $87.38 Week Perf: 1.22 %
Day's Low: $ 84.02 30 Day Perf: 13.96 %
Volume (M): 312 52 Wk High: $ 87.47
Volume (M$): $ 27,208 52 Wk Avg: $50.52
Open: $84.95 52 Wk Low: $23.10

 Market Capitalization (Millions $) 4,982
 Shares Outstanding (Millions) 57
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -114
 Cash Flow (TTM) (Millions $) 12
 Capital Exp. (TTM) (Millions $) 0

Nuvalent Inc
Nuvalent Inc is a biopharmaceutical company that focuses on the discovery and development of targeted cancer therapies. The company is dedicated to addressing unmet medical needs in cancer treatment by identifying and developing innovative drug candidates. Nuvalent Inc uses their expertise in precision medicine and oncology research to develop therapies that specifically target the genetic mutations driving cancer growth. Their goal is to provide patients with better treatment options and improve outcomes in cancer care.

   Company Address: One Broadway Cambridge 2142 MA
   Company Phone Number: 357-7000   Stock Exchange / Ticker: NASDAQ NUVL
   NUVL is expected to report next financial results on March 15, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Nuvalent Inc

Nuvalent Inc Faces Increasing Financial Struggles with $-38.783 Million Operating Loss in Third Quarter of 2023

Nuvalent Inc, a pharmaceutical company trading on the NASDAQ, has recently reported its financial results for the third quarter of 2023. While the stock has shown improvement over the past week and has a strong year-to-date performance, the company's operating loss and increasing deficit raise concerns about its future growth prospects. In this article, we will analyze the facts and explore how these financial indicators might impact Nuvalent Inc going forward.
1. Operating Loss:
During the third quarter of 2023, Nuvalent Inc reported an operating loss of $-38.783 million, a significant increase from the previous year's third quarter loss of $-20.388 million. This sudden rise in operating loss indicates potential challenges in the company's operational efficiency. Furthermore, it raises questions about the effectiveness of Nuvalent Inc's current strategies and policies in generating revenue.

Nuvalent Inc

Nuvalent Inc witnesses substantial growth in existing outlays during recent fiscal period causing concern among shareholders

Investors were caught off guard by unexpected adjustments made at Nuvalent Inc during the earnings cycle from April to June 30, 2023. The company has not yet announced its revenue for this period, but it is anticipated that the latest results will shed light on the company's current performance.
One concerning factor for shareholders is the operating shortfall, which stood at $-34.062 million during this time frame. To provide context, it is worth comparing this figure to the same period in 2022, where the company reported an operating shortfall of $-18.733 million. This indicates a significant increase in the shortfall, highlighting potential challenges faced by Nuvalent Inc.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com